1. Home
  2. JMM vs CTSO Comparison

JMM vs CTSO Comparison

Compare JMM & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Multi-Market Income Fund (MA)

JMM

Nuveen Multi-Market Income Fund (MA)

HOLD

Current Price

$6.13

Market Cap

58.1M

Sector

Finance

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.72

Market Cap

49.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JMM
CTSO
Founded
1988
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
49.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JMM
CTSO
Price
$6.13
$0.72
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
16.1K
126.1K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
5.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,979,520.00
Revenue This Year
N/A
$9.51
Revenue Next Year
N/A
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$5.29
$0.60
52 Week High
$6.10
$1.61

Technical Indicators

Market Signals
Indicator
JMM
CTSO
Relative Strength Index (RSI) 43.12 46.64
Support Level $6.06 $0.70
Resistance Level $6.15 $0.85
Average True Range (ATR) 0.04 0.07
MACD 0.00 0.01
Stochastic Oscillator 35.71 52.04

Price Performance

Historical Comparison
JMM
CTSO

About JMM Nuveen Multi-Market Income Fund (MA)

Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: